AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10657421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical and imaging variables
Number of subjects: 256
Study 10657421 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 256
Study 10657421 — intervention group
Group type: COMPARATOR
Intervention: Imaging variables alone
Number of subjects: 256
Study 9310008 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal manometry during polysomnography
Number of subjects: 155
Study 9310008 — intervention group
Group type: COMPARATOR
Intervention: Matched control group without esophageal catheters
Number of subjects: 155
Study 8220802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannic acid
Number of subjects: 52
Study 8220802 — intervention group
Group type: EXPERIMENTAL
Intervention: Central vacuum cleaners
Number of subjects: 52
Study 8220802 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA vacuum cleaners
Number of subjects: 52
Study 8220802 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-filter vacuum cleaners
Number of subjects: 52
Study 8220802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3295148 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing (Warfcalc)
Number of subjects: 75
Study 31664515 — intervention group
Group type: EXPERIMENTAL
Intervention: hemithyroidectomy with prophylactic ipsilateral central neck dissection (pCND)
Number of subjects: 164
Study 31664515 — intervention group
Group type: COMPARATOR
Intervention: hemithyroidectomy without prophylactic ipsilateral central neck dissection (pCND)
Number of subjects: 164
Study 29736742 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant Balm (PB) applied 2-3 times/day
Number of subjects: 60
Study 29736742 — intervention group
Group type: COMPARATOR
Intervention: Petroleum Control (PC)
Number of subjects: 60
Study 29736742 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant Balm (PB)
Number of subjects: 60
Study 28504313 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical see-through head-mounted display (OST-HMD)
Number of subjects: 2
Study 28504313 — intervention group
Group type: COMPARATOR
Intervention: Normal ultrasound monitor
Number of subjects: 2
Study 26714284 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG-HD trial (intervention group)
Number of subjects: 93
Study 26714284 — intervention group
Group type: COMPARATOR
Intervention: RIL-HD trial (placebo control group)
Number of subjects: 93
Study 22780449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 23
Study 22780449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 21490036 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT 'on' (day 0)
Number of subjects: 16
Study 21490036 — intervention group
Group type: COMPARATOR
Intervention: CRT 'off' (day 14)
Number of subjects: 16
Study 21490036 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT re‐initiation (day 14)
Number of subjects: 16
Study 21490036 — intervention group
Group type: COMPARATOR
Intervention: CRT cessation
Number of subjects: 16
Study 21490036 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT re‐initiation
Number of subjects: 16
Study 18986746 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer educator, network-oriented intervention
Number of subjects: 983
Study 18986746 — intervention group
Group type: COMPARATOR
Intervention: Life-skills intervention
Number of subjects: 983
Study 18986746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 983
Study 17298754 — intervention group
Group type: EXPERIMENTAL
Intervention: External plus intracavitary irradiation (58-62 Gy external + 15-20 Gy intracavitary)
Number of subjects: 321
Study 17298754 — intervention group
Group type: COMPARATOR
Intervention: Conventional irradiation (66-74 Gy)
Number of subjects: 321
Study 15544714 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate altitude (1,700 m) vacation
Number of subjects: 72
Study 15544714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low altitude (300 m) vacation
Number of subjects: 72
Study 15544714 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after vacation
Number of subjects: 72
Study 15544714 — intervention group
Group type: EXPERIMENTAL
Intervention: Active individuals
Number of subjects: 72
Study 11502903 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 300 mg twice daily
Number of subjects: 347
Study 11502903 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 200 mg three times daily
Number of subjects: 347
Study 11502903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both coenzyme Q10 and remacemide
Number of subjects: 347
Study 11502903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (neither treatment)
Number of subjects: 347
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol-binding protein
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Prealbumin
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A to retinol-binding protein ratio
Number of subjects: 467
Study 9240872 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient deficiency prevalence
Number of subjects: 467
Study 7963729 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV subunit vaccine (rgp120SF2) combined with MF59 adjuvant
Number of subjects: 42
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg)
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg)
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and all beta-blocker/felodipine combinations
Number of subjects: 10
Study 2442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine/beta-blocker combinations
Number of subjects: 10
Study 28463904 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-down positioning (FDP)
Number of subjects: 68
Study 28463904 — intervention group
Group type: COMPARATOR
Intervention: Nonsupine positioning (NSP)
Number of subjects: 68
Study 28463904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas fill
Number of subjects: 68
Study 28463904 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning (FDP or NSP)
Number of subjects: 68
Study 28463904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-foveal contact
Number of subjects: 68
Study 28167477 — intervention group
Group type: EXPERIMENTAL
Intervention: Entoban capsule 400mg every 8 hours for five days
Number of subjects: 150
Study 28167477 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole tablets (400 mg) for 7‐10 days
Number of subjects: 150
Study 25639660 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte telomere length
Number of subjects: 3275
Study 25639660 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin treatment
Number of subjects: 3275
Study 23547489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning with meridol HALITOSIS tooth & tongue gel (C)
Number of subjects: 54
Study 23547489 — intervention group
Group type: COMPARATOR
Intervention: Mechanical tongue cleaning alone (B)
Number of subjects: 54
Study 23547489 — intervention group
Group type: COMPARATOR
Intervention: No treatment (A)
Number of subjects: 54
Study 21288078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg twice daily for 10 days)
Number of subjects: 629
Study 21288078 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times daily for 10 days)
Number of subjects: 629
Study 21288078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 629
Study 21288078 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 629
Study 19463375 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*1*1 carriers after a 600-mg dose
Number of subjects: 60
Study 19463375 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19*2 or *4 carriers after a 600-mg dose
Number of subjects: 60
Study 19463375 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19*17 carriers after a 600-mg dose
Number of subjects: 60
Study 19463375 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 or *4 carriers with higher loading dose at 4 h
Number of subjects: 60
Study 19463375 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 or *4 carriers with higher maintenance dose regimen
Number of subjects: 60
Study 16650414 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin A
Number of subjects: 35
Study 16650414 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 35
Study 16650414 — intervention group
Group type: EXPERIMENTAL
Intervention: Activin A
Number of subjects: 35
Study 16650414 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid concentrations
Number of subjects: 35
Study 16650414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte retrieval
Number of subjects: 35
Study 14749149 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 + ROS (biphasic insulin aspart 30 plus rosiglitazone 4 mg once daily)
Number of subjects: 49
Study 14749149 — intervention group
Group type: COMPARATOR
Intervention: GLIB + ROS (glibenclamide plus rosiglitazone 4 mg once daily)
Number of subjects: 49
Study 10826396 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 16 mg/day)
Number of subjects: 70
Study 10826396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8858401 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/day for 3 weeks)
Number of subjects: 6
Study 8858401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/day for 3 weeks)
Number of subjects: 6
Study 1298591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaura
Number of subjects: 223
Study 1298591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 6373165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide 1 gm every twelve hours
Number of subjects: 96
Study 6373165 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 1 gm every eight hours
Number of subjects: 96
Study 31787004 — intervention group
Group type: EXPERIMENTAL
Intervention: Close contact casting (CCC)
Number of subjects: 620
Study 31787004 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (surgery)
Number of subjects: 620
Study 29439704 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) patterns
Number of subjects: 1131
Study 29439704 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated spurt (IS) and clustered spurt (CS) MVPA
Number of subjects: 1131
Study 29439704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered sustained activity (CSA)
Number of subjects: 1131
Study 24995700 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective iron group (elemental iron 50 mg twice a day if diagnosed as anaemic)
Number of subjects: 2944
Study 24995700 — intervention group
Group type: COMPARATOR
Intervention: Routine iron group (elemental iron 100 mg day(‐1) throughout pregnancy)
Number of subjects: 2944
Study 24995700 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective iron group
Number of subjects: 2944
Study 24995700 — intervention group
Group type: COMPARATOR
Intervention: Routine iron group
Number of subjects: 2944
Study 24604614 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 14
Study 24604614 — intervention group
Group type: EXPERIMENTAL
Intervention: li‐rIPC
Number of subjects: 14
Study 22762951 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer change agent (PCA) identification and recruitment methodology based on social network analysis.
Number of subjects: 25
Study 22762951 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of friendship dynamics among truck-drivers.
Number of subjects: 25
Study 22762951 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network influences and risk reduction discussions.
Number of subjects: 25
Study 22762951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot testing of PCA identification approach.
Number of subjects: 25
Study 20170482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multi-factorial cardiovascular risk intervention
Number of subjects: 285
Study 20170482 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (according to current national guidelines)
Number of subjects: 285
Study 17919489 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-specific CD8 T-cell response before treatment
Number of subjects: 32
Study 17919489 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-specific CD8 T-cell responses during the first weeks of therapy
Number of subjects: 32
Study 17919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Late treatment phase T-cell responses
Number of subjects: 32
Study 17919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HCV-specific CD8 cell proliferative potential
Number of subjects: 32
Study 15472652 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium fixation
Number of subjects: 60
Study 15472652 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable fixation
Number of subjects: 60
Study 11570617 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast, 20 mg twice daily
Number of subjects: 18
Study 11570617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9924306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic laser treatment (argon green laser, approximately 100 mild laser burns)
Number of subjects: 36
Study 9924306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 7997324 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (topical prednisolone phosphate)
Number of subjects: 106
Study 7997324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 2656266 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 23
Study 5031656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 14
Study 5031656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 14
Study 5031656 — intervention group
Group type: EXPERIMENTAL
Intervention: Other metabolic products of propranolol
Number of subjects: 14
Study 5031656 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidentified major metabolites of propranolol
Number of subjects: 14
Study 31585796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 500 mL of crystalloid solution
Number of subjects: 337
Study 31585796 — intervention group
Group type: COMPARATOR
Intervention: No fluid bolus
Number of subjects: 337
Study 28095397 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, oxaliplatin and capecitabine (EOX)
Number of subjects: 55
Study 28095397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and capecitabine (OX)
Number of subjects: 55
Study 28095397 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine alone (X)
Number of subjects: 55
Study 28095397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment utility (OTU)
Number of subjects: 55
Study 28095397 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-haematologic toxicity >grade 3
Number of subjects: 55
Study 25769361 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban (60 mg once daily)
Number of subjects: 21105
Study 25769361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban (30 mg once daily)
Number of subjects: 21105
Study 25769361 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose adjusted to INR 2.0-3.0)
Number of subjects: 21105
Study 22983832 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 120
Study 21256626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/Propofol
Number of subjects: 193
Study 21256626 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 193
Study 19996654 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral EMP 10 mg/kg in 3 doses
Number of subjects: 56
Study 19996654 — intervention group
Group type: COMPARATOR
Intervention: Low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m(2) once daily on days 1 through 14
Number of subjects: 56
Study 16335163 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded TiUnite implants
Number of subjects: 35
Study 16335163 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants (control)
Number of subjects: 35
Study 12077735 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus 1 mg hydroxocobalamin administered subcutaneously once per week after dialysis
Number of subjects: 24
Study 12077735 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (5 to 6 mg folic acid, 5 to 10 mg pyridoxine, and 6 to 10 microg oral vitamin B(12) per day)
Number of subjects: 24
Study 9860110 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 20 mg
Number of subjects: 12
Study 9860110 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 40 mg
Number of subjects: 12
Study 9860110 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 12
Study 9860110 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 120 mg
Number of subjects: 12
Study 9860110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8553795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 18
Study 2243253 — intervention group
Group type: EXPERIMENTAL
Intervention: Various randomization procedures (total randomization, Zelen-type, Efron-type, Simon-Pocock-type)
Number of subjects: 0
Study 219964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (13 courses of three infusions over 3 years, each infusion containing 12 mg/kg cyclophosphamide, 12 mg/kg 5‐fluorouracil, 0.5 mg/kg methotrexate, 0.1 mg/kg vinblastine)
Number of subjects: 219
Study 219964 — intervention group
Group type: COMPARATOR
Intervention: Control group (radical surgery only)
Number of subjects: 219
Study 30336181 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab in combination with methotrexate (20 or 40 mg, according to body weight)
Number of subjects: 0
Study 30336181 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (up to 25 mg weekly)
Number of subjects: 0
Study 28949162 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical randomized algorithm for approximating the partition function
Number of subjects: 0
Study 28949162 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynomial time algorithm for approximating free energy or ground energy
Number of subjects: 0
Study 28949162 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect matching sum of a finite graph with positive edge weights
Number of subjects: 0
Study 26036878 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary-like pancreaticojejunostomy
Number of subjects: 308
Study 26036878 — intervention group
Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy
Number of subjects: 308
Study 23936144 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 20
Study 23936144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21751690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (4 microg/kg)
Number of subjects: 41
Study 21751690 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 41
Study 19433147 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase physical activity
Number of subjects: 0
Study 19433147 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduce stress through meditating
Number of subjects: 0
Study 19433147 — intervention group
Group type: COMPARATOR
Intervention: No-change control group
Number of subjects: 0
Study 17143593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoral stretching program (daily low-load, prolonged stretches)
Number of subjects: 64
Study 17143593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise advice)
Number of subjects: 64
Study 17143593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stretch and control)
Number of subjects: 64
Study 14730599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone
Number of subjects: 195
Study 14730599 — intervention group
Group type: COMPARATOR
Intervention: Single therapy with a DMARD with or without prednisolone
Number of subjects: 195
Study 12575592 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus Chinese drugs combined treatment
Number of subjects: 153
Study 12575592 — intervention group
Group type: COMPARATOR
Intervention: Simple antibiotics treatment
Number of subjects: 153
Study 9456641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate (Peridex) mouthrinses, twice daily for 6 days per week, supervised for 3 months
Number of subjects: 60
Study 9456641 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinses, twice daily for 6 days per week, supervised for 3 months
Number of subjects: 60
Study 8194639 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical lubricants
Number of subjects: 0
Study 3285535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and prednisone
Number of subjects: 108
Study 3285535 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza) and glucocorticoids
Number of subjects: 108
Study 3285535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 108